Febuxostat
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Febuxostat and local guidelines before prescribing.
Mechanism
Non-purine xanthine oxidase inhibitor.
Uses
Chronic gout when allopurinol unsuitable.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Gout flares at start, raised LFT, nausea, cardiovascular death signal.
Interactions
Azathioprine and mercaptopurine toxicity.
Contraindications and cautions
Ischaemic heart disease, heart failure
Monitoring
Urate, LFT
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Caution in severe renal or hepatic impairment
Overdose and reversal
Supportive
Special advice
Use colchicine or NSAID cover for the first months; avoid in established cardiovascular disease.
More from the textbook: uses, cautions and other points
- Azathioprine | Bone marrow suppression; check TPMT; avoid allopurinol and febuxostat; safe in pregnancy.
Renal: Dialysis and Transplant - Febuxostat — non-purine xanthine oxidase inhibitor — second line; caution in cardiovascular disease (MHRA — increased CV mortality in one trial).
Rheumatology Anatomy Physiology Pharmacology - Azathioprine | SLE, vasculitis maintenance, myositis, steroid sparing | Check TPMT activity before starting (low - high risk of marrow suppression); avoid with allopurinol or febuxostat (dangerous marrow toxicity); hepatitis, pancreatitis, skin cancer; safe in pregnancy
Rheumatology: assessment, investigations and drugs - Febuxostat - if allopurinol is not tolerated or not effective; caution in major cardiovascular disease (MHRA) - allopurinol is preferred in those patients.
Rheumatology: Crystal arthritis, osteoarthritis and soft tissue pain - Interaction - azathioprine and mercaptopurine with allopurinol or febuxostat → severe marrow toxicity - avoid or greatly reduce the dose (specialist).
Rheumatology: Crystal arthritis, osteoarthritis and soft tissue pain - CKD - gout is common; colchicine and NSAIDs are limited - use steroids for flares; allopurinol is still used (start low, increase slowly to target - not limited by eGFR-based maximums if monitored); febuxostat needs no dose change in mild to moderate CKD.
Rheumatology: Crystal arthritis, osteoarthritis and soft tissue pain - Febuxostat - caution in major cardiovascular disease.
Rheumatology: Crystal arthritis, osteoarthritis and soft tissue pain - Hyperuricaemia and gout - common; allopurinol (dose-adjust) or febuxostat; don't treat raised urate without gout to protect the kidneys (no benefit in trials).
Renal: Chronic Kidney Disease
Where it is discussed in the book
- Renal: Chronic Kidney Disease (1 mention)
- Renal: Dialysis and Transplant (1 mention)
- Rheumatology Anatomy Physiology Pharmacology (2 mentions)
- Rheumatology: assessment, investigations and drugs (1 mention)
- Rheumatology: Crystal arthritis, osteoarthritis and soft tissue pain (5 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Biochemistry: Metabolism of carbohydrates, lipids and proteins (1 mention)